2024/01/31 更新

写真a

ヨシオ コウタロウ
吉尾 浩太郎
YOSHIO Koutarou
所属
医歯薬学域 講師(特任)
職名
講師(特任)
外部リンク

学位

  • 博士(医学) ( 岡山大学 )

 

論文

  • Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.

    Hiroki Ihara, Kotaro Yoshio, Shunsuke Tanabe, Soichi Sugiyama, Masashi Hashimoto, Naoaki Maeda, Shinsuke Akagi, Soshi Takao, Kazuhiro Noma, Takao Hiraki

    Esophagus : official journal of the Japan Esophageal Society   20 ( 3 )   548 - 556   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Surgical resection of esophageal cancer is frequently performed to achieve a complete cure. However, the postoperative recurrence rate is 36.8-42.5%, leading to poor prognosis. Radiation therapy has been used to treat recurrences; solitary recurrence has been proposed as a prognostic factor for radiation therapy, though its significance is unclear. 18F-fluorodeoxyglucose positron emission tomography is a highly accurate diagnostic modality for esophageal cancer. This retrospective study aimed to analyze the outcomes of solitary postoperative recurrences of esophageal squamous cell carcinoma diagnosed with 18F-fluorodeoxyglucose positron emission tomography and treated with definitive radiation therapy. METHODS: We examined 27 patients who underwent definitive radiation therapy for single or multiple postoperative recurrences of esophageal squamous cell carcinoma between May 2015 and April 2021. 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed within 3 months before the commencement of radiation therapy. Kaplan-Meier, univariate, and multivariate analyses were performed to examine the overall survival and identify potential prognostic factors. RESULTS: The 1-, 2-, and 3-year overall survival rates were 85.2%, 62.6%, and 47.3%, respectively, and solitary recurrence was the only significant factor associated with overall survival (P = 0.003). The 1-, 2-, and 3-year overall survival rates in patients with solitary recurrence were 91.7%, 80.2%, and 80.2%, respectively, and in patients with multiple recurrences they were 80.0%, 50.3%, and 25.1%, respectively. Multivariate analysis also showed solitary recurrence as a significant factor for overall survival. CONCLUSIONS: When diagnosed with 18F-fluorodeoxyglucose positron emission tomography/computed tomography, solitary recurrence appears to have a more favorable prognosis than multiple recurrences.

    DOI: 10.1007/s10388-023-01000-4

    PubMed

    researchmap

  • Tumor size before image-guided brachytherapy is an important factor of local control after radiotherapy for cervical squamous cell carcinoma: analysis in cases using central shielding. 国際誌

    Kotaro Yoshio, Hiroki Ihara, Kazuhiro Okamoto, Etsuji Suzuki, Takeshi Ogata, Soichi Sugiyama, Keiichiro Nakamura, Shoji Nagao, Hisashi Masuyama, Takao Hiraki

    Journal of radiation research   63 ( 5 )   772 - 779   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We analyzed the local control (LC) of cervical squamous cell carcinoma treated by computed tomography (CT)-based image-guided brachytherapy (IGBT) using central shielding (CS). We also examined the value of tumor diameter before brachytherapy (BT) as a factor of LC. In total, 97 patients were analyzed between April 2016 and March 2020. Whole-pelvic (WP) radiotherapy (RT) with CS was performed, and the total pelvic sidewall dose was 50 or 50.4 Gy; IGBT was delivered in 3-4 fractions. The total dose was calculated as the biologically equivalent dose in 2 Gy fractions, and distribution was modified manually by graphical optimization. The median follow-up period was 31.8 months (6.3-63.2 months). The 1- and 2-year LC rates were 89% and 87%, respectively. The hazard ratio was 10.11 (95% confidence interval: 1.48-68.99) for local recurrence in those with a horizontal tumor diameter ≥ 4 cm compared to those with < 4 cm before BT. In CT-based IGBT for squamous cell carcinoma, favorable LC can be obtained in patients with a tumor diameter < 4 cm before BT. However, if the tumor diameter is ≥ 4 cm, different treatment strategies such as employing interstitial-BT for dose escalation may be necessary.

    DOI: 10.1093/jrr/rrac040

    PubMed

    researchmap

  • Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Scientific Reports   11 ( 1 )   11882 - 11882   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title>We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28–6.64 for PS, and 2.36 and 1.15–4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.

    DOI: 10.1038/s41598-021-91449-z

    PubMed

    researchmap

    その他リンク: http://www.nature.com/articles/s41598-021-91449-z

  • Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study 査読 国際誌

    Kenta Watanabe, Kuniaki Katsui, Soichiro Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Radiation Oncology   16 ( 1 )   39 - 39   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title><sec>
    <title>Background</title>
    Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidities. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients aged ≥ 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC.


    </sec><sec>
    <title>Methods</title>
    We retrospectively evaluated the data of patients aged ≥ 80 years with pathologically proven primary NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and toxicities were analyzed. We used the Kaplan–Meier method to estimate survival curves and the log-rank test to compare the survival curves. We performed univariate and multivariate Cox regression analyses. <italic>p</italic>-values &lt; 0.05 were regarded significant.


    </sec><sec>
    <title>Results</title>
    Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5–95.7) months. The median age was 82.9 (range 80.0–94.8) years. Sixteen patients were medically operable, and 48 patients were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The median survival time was 60.0 months (95% confidence interval, 43.5–71.1). The 1-, 3-, and 5-year local control, cancer-specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoperability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis.


    </sec><sec>
    <title>Conclusions</title>
    SBRT was feasible in patients aged ≥ 80 years with NSCLC. It achieved good local control with minimal toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.


    </sec>

    DOI: 10.1186/s13014-021-01769-7

    PubMed

    researchmap

    その他リンク: http://link.springer.com/article/10.1186/s13014-021-01769-7/fulltext.html

  • Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer 査読

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Masaomi Yamane, Takao Hiraki, Katsuyuki Kiura, Shinichi Toyooka, Susumu Kanazawa

    International Journal of Clinical Oncology   26 ( 8 )   1450 - 1460   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    BACKGROUND: The association between sarcopenia and prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing trimodality therapy, consisting of preoperative concurrent chemoradiotherapy and surgery, has not been reported. Therefore, we aimed to investigate the association of sarcopenia and fat mass with prognosis after trimodality therapy. METHODS: To assess sarcopenia, the psoas muscle mass was measured. Using computed tomography data, including third lumbar vertebra level images, psoas muscle mass and visceral and subcutaneous fat mass were measured. Additionally, body mass indices, and visceral/subcutaneous fat ratio, obtained by dividing the visceral fat index by the subcutaneous fat index, were calculated. We investigated the relationship between these parameters and overall survival. RESULTS: Ninety-nine eligible patients were included. In the univariate analysis, age, clinical stage, tumor location, psoas muscle index, and visceral/subcutaneous fat ratio were significant prognostic factors for overall survival (P = 0.008, P = 0.04, P = 0.04, P = 0.02, and P = 0.02, respectively). In the multivariate analysis, age and psoas muscle index were significant prognostic factors for overall survival (P = 0.01 and P = 0.03, respectively). The 5-year overall survival rates for the high and low psoas muscle index groups were 79.6% [95% confidence interval (CI), 67.1-94.5%] and 66.2% (95% CI, 54.1-81.1%), respectively; whereas, the 10-year overall survival rates were 61.9% (95% CI, 42.0-91.4%) and 25.3% (95% CI, 8.6-74.2%), respectively. CONCLUSION: Sarcopenia was related to poor overall survival in patients with locally advanced NSCLC undergoing trimodality therapy. Assessment of body composition prior to treatment may provide important information for formulating rational therapeutic strategies.

    DOI: 10.1007/s10147-021-01927-7

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1007/s10147-021-01927-7/fulltext.html

  • New field‑in‑field with two reference points method for whole breast radiotherapy: Dosimetric analysis and radiation‑induced skin toxicities assessment 査読 国際誌

    Nouha Tekiki, Masahiro Kuroda, Hinata Ishizaka, Abdullah Khasawneh, Majd Barham, Kentaro Hamada, Kohei Konishi, Kohei Sugimoto, Kuniaki Katsui, Soichi Sugiyama, Kenta Watanabe, Kotaro Yoshio, Norihisa Katayama, Takeshi Ogata, Hiroki Ihara, Susumu Kanazawa, Junichi Asaumi

    Molecular and Clinical Oncology   15 ( 3 )   193 - 193   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Spandidos Publications  

    The usefulness of the field-in-field with two reference points (FIF w/ 2RP) method, in which the dose reference points are set simultaneously at two positions in the irradiation field and the high-dose range is completely eliminated, was examined in the present study with the aim of decreasing acute skin toxicity in adjuvant breast radiotherapy (RT). A total of 573 patients with breast cancer who underwent postoperative whole breast RT were classified into 178 cases with wedge (W) method, 142 cases with field-in-field without 2 reference points (FIF w/o 2RP) method and 253 cases with FIF w/ 2RP method. Using the FIF w/ 2RP method, the high-dose range was the lowest among the three irradiation methods. The planning target volume (PTV) V105% and the breast PTV for evaluation (BPe) V105% decreased to 0.09 and 0.10%, respectively. The FIF w/ 2RP method vs. the FIF w/o 2RP method had a strong association (η) with PTV V105% (η=0.79; P<0.001) and BPe V105% (η=0.76; P<0.001). The FIF w/ 2RP method had a significant impact on lowering the skin toxicity grade in weeks 3 and 4, and increasing the occurrence of skin toxicity grade 0. The FIF w/ 2RP method vs. the W method had a moderate association with skin toxicity grade at week 3 (η=0.49; P<0.001). Using the FIF w/ 2RP method, the high-dose range V105% of the target decreased to 0%, and skin adverse events were decreased in conjunction. For patients with early-stage breast cancer, particularly patients with relatively small-sized breasts, the FIF w/ 2RP method may be an optimal irradiation method.

    DOI: 10.3892/mco.2021.2355

    PubMed

    researchmap

  • Publisher Correction: Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis. 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Scientific reports   11 ( 1 )   14586 - 14586   2021年7月

     詳細を見る

  • Investigation into the Effect of Breast Volume on Irradiation Dose Distribution in Asian Women with Breast Cancer. 査読

    Hinata Ishizaka, Masahiro Kuroda, Nouha Tekiki, Abdullah Khasawneh, Majd Barham, Kentaro Hamada, Kohei Konishi, Kohei Sugimoto, Kuniaki Katsui, Soichi Sugiyama, Kenta Watanabe, Kotaro Yoshio, Norihisa Katayama, Takeshi Ogata, Hiroki Ihara, Masataka Oita, Susumu Kanazawa, Junichi Asaumi

    Acta medica Okayama   75 ( 3 )   307 - 314   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Reports on irradiation dose distribution in breast cancer radiotherapy with sufficient sample size are limited in Asian patients. Elucidating dose distribution in Asian patients is particularly important as their breast volume differs compared to patients in Europe and North America. Here, we examined dose distribution in the irradiation field relative to breast volume for three irradiation methods historically used in our facility. We investigated the influence of breast volume on each irradiation method for Asian women. A total of 573 women with early-stage breast cancer were treated with breast-conserving surgery and adjuvant radiotherapy. Three methods were compared: wedge (W), field-in-field (FIF), and wedge-field-in-field (W-FIF). In patients with small breast volume, FIF decreased low- and high-dose areas within the planning target volume, and increased optimal dose area more than W. In patients with medium and large breast volumes, FIF decreased high-dose area more than W. The absolute values of correlation coefficients of breast volume to low-, optimal-, and high-dose areas and mean dose were significantly lower in FIF than in W. The correlation coefficients of V107% were 0.00 and 0.28 for FIF and W, respectively. FIF is an excellent irradiation method that is less affected by breast volume than W in Asian breast cancer patients.

    DOI: 10.18926/AMO/62225

    PubMed

    researchmap

  • Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer. 査読

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Acta medica Okayama   75 ( 3 )   269 - 277   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Palliative concurrent chemoradiotherapy (CCRT) is often administered to patients with stage III non-small cell lung cancer (NSCLC). We investigated the clinical outcomes of patients receiving palliative CCRT for NSCLC. Data of patients with NSCLC who underwent palliative CCRT (n=16), preoperative CCRT plus surgery (n=97), or definitive CCRT (n=48) were evaluated. In all groups, the concurrent chemotherapy regimens consisted of cisplatin and docetaxel. Rates of local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), overall survival (OS), and prognosis were compared. The 2-year rates of LC, DMFS, PFS, and OS in 16 patients who underwent palliative CCRT were 44.4%, 12.5%, 12.5%, and 18.8%, respectively. Univariate analysis showed that palliative CCRT was associated with poor LC (p<0.001), DMFS (p<0.001), PFS (p<0.001), and OS (p<0.001) outcomes in patients who completed CCRT as a preoperative treatment and poor LC (p=0.01), DMFS (p=0.003), PFS (p=0.04), and OS (p=0.004) outcomes in patients who were considered for definitive CCRT. Although there were some long-term survivors, the clinical outcomes of palliative CCRT were significantly inferior to those of the ideal treatments. Therefore, careful determination of the appropriate treatment indications and further studies are warranted.

    DOI: 10.18926/AMO/62218

    PubMed

    researchmap

  • A PET/CT volumetric parameter predicts prognosis of non‑small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Akihiro Tada, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Shinichi Toyooka, Susumu Kanazawa

    Molecular and Clinical Oncology   14 ( 4 )   73 - 73   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Spandidos Publications  

    The purpose of the present study was to clarify whether positron emission tomography/computed tomography (PET/CT) volumetric parameters were prognostic predictors of non-small cell lung cancer (NSCLC) treatment in patients who had undergone preoperative concurrent chemoradiotherapy (CCRT) and surgery. In the present study, retrospectively surveyed the data of patients with NSCLC who underwent preoperative CCRT and surgery at Okayama University Hospital (Okayama, Japan) between April 2006 and March 2018. The maximum standardized uptake value (SUVmax) and volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were calculated using PET/CT and the percentage decrease (Δ) in each parameter value post-CCRT. The SUVmax threshold for defining MTV was set at 2.5. Furthermore, the association between survival and PET parameter values was analyzed. A total of 52 patients were included in the present study. The median follow-up period was 50.65 months. In univariate analysis, ΔTLG was identified to be a significant predictor of progression-free survival (PFS; P=0.03). The 5-year PFS rates were 48.6 and 76.6% for patients with low ΔTLG and high ΔTLG, respectively. High ΔTLG was indicative of a higher overall survival rate (P=0.08). The present results suggest that ΔTLG calculated using PET/CT is a prognostic predictor of NSCLC treated using preoperative CCRT and surgery, and may help physicians determine treatment strategies.

    DOI: 10.3892/mco.2021.2235

    PubMed

    researchmap

  • Volumetric PET Parameters Predict Prognosis after Definitive Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-Small Cell Lung Cancer. 査読

    Kuniaki Katsui, Takeshi Ogata, Akihiro Tada, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Takao Hiraki, Susumu Kanazawa

    Acta medica Okayama   75 ( 1 )   15 - 23   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.

    DOI: 10.18926/AMO/61429

    PubMed

    researchmap

  • Local Control of Squamous Cell Carcinoma of the Cervix Treated with CT-based Three-dimensional Image-Guided Brachytherapy with or without Central Shielding 査読

    Kotaro Yoshio, Hisako Nagasaka, Kento Hisazumi, Hiro Okawa, Nobuhisa Tajiri, Tsuyoki Shiode, Shiro Akaki, Susumu Kanazawa, Tomohiro Mitoma, Yuri Yano, Emiko Kobayashi, Ikuyo Horiguchi, Masayo Takata, Atsushi Hongo, Masaru Yonezawa, Yoshie Nakanishi

    Acta Medica Okayama   75 ( 1 )   79 - 85   2021年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The purposes of this retrospective study were to analyze local control of squamous cell carcinoma of the cervix treated with computed tomography (CT)-based image-guided brachytherapy (IGBT), as well as the factors affecting local control. A total of 39 patients were analyzed. The prescribed dose to the pelvis was 45-50 Gy with or without central shielding (CS). IGBT was delivered in 1-5 fractions. The total dose for high-risk clinical target volume (HR-CTV) was calculated as the biologically equivalent dose in 2-Gy fractions. The median follow-up period was 29.3 months. The 2-year overall survival and local control rates were 97% and 91%, respectively. In univariate analysis, the dose covering 90% of the HR-CTV (D90) and tumor size were found to be significant factors for local control. The cutoff values of tumor size and D90 for local control were 4.3 cm (area under the curve [AUC] 0.75) and 67.7 Gy (AUC 0.84) in the CS group and 5.3 cm (AUC 0.75) and 73.7 Gy (AUC 0.78) in the group without CS, respectively. However, though the local control of CT-based IGBT was favorable, the results suggested that the dose required for tumor control may differ depending on the presence of CS.

    DOI: 10.18926/AMO/61438

    PubMed

    researchmap

  • Visceral Adipose Mass and Radiation Pneumonitis After Concurrent Chemoradiotherapy in Patients With Non-small-cell Lung Cancer. 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Masaomi Yamane, Takao Hiraki, Katsuyuki Kiura, Shinichi Toyooka, Susumu Kanazawa

    Cancer diagnosis & prognosis   1 ( 2 )   61 - 67   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: To investigate whether muscle and adipose mass are associated with radiation pneumonitis (RP) in patients with non-small cell lung cancer undergoing preoperative concurrent chemoradiotherapy. PATIENTS AND METHODS: We calculated body mass index and determined skeletal muscle, psoas muscle, visceral adipose tissue (VAI), and subcutaneous adipose tissue indices, and visceral-to-subcutaneous adipose tissue area ratio for patients using computed tomography. We examined their relationship with grade 2 or more RP. RESULTS: Among 94 patients, 28 experienced grade 2 or more RP. On multivariate analysis, only VAI was associated with grade 2 or more RP (all p=0.026). The 6-month incidence rates of grade 2 or more RP were 21.4% and 36.8% in patients with VAI <39 and ≥39 cm 2 /m 2 , respectively. CONCLUSION: High visceral adipose mass is associated with grade 2 or more RP in patients undergoing preoperative concurrent chemoradiotherapy. Measuring visceral adipose mass may help to predict RP occurrence. Further studies are needed to validate our findings.

    DOI: 10.21873/cdp.10009

    PubMed

    researchmap

  • Feasibility of 5-mm vs 2.5-mm width multileaf collimator in noncoplanar volumetric modulated arc stereotactic radiotherapy for multiple brain metastases 査読

    Kotaro Yoshio, Akihisa Wakita, Kento Hisazumi, Takahiro Kitayama, Nobuhisa Tajiri, Tsuyoki Shiode, Shiro Akaki, Susumu Kanazawa

    Medical Dosimetry   45 ( 1 )   97 - 101   2020年

     詳細を見る

    担当区分:筆頭著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.meddos.2019.07.006

    researchmap

  • Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Middle or Lower Esophageal Cancer Using Elective Nodal Irradiation: Comparison with 3D Conformal Radiotherapy. 査読

    Kotaro Yoshio, Akihisa Wakita, Toshiharu Mitsuhashi, Takahiro Kitayama, Kento Hisazumi, Daisaku Inoue, Nobuhisa Tajiri, Tsuyoki Shiode, Shiro Akaki, Susumu Kanazawa

    Acta medica Okayama   73 ( 3 )   247 - 257   2019年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We investigated the feasibility of simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) using elective nodal irradiation (ENI) for middle or lower esophageal cancer and compared it with three-dimensional conformal radiotherapy (3D-CRT). The study included 15 patients. The prescribed doses included a standard dose (50.4 Gy) and a high dose (60 Gy) for the planning target volume (PTV) of the involved lesions. The objective of the whole lung volume receiving ≥ 20 Gy (V20Gy) was < 30%, and the mean lung dose (MLD) was < 20 Gy. The volumes of the lung receiving 5 Gy (V5Gy) and the heart receiving 30-50 Gy (V30-50Gy) were kept as low as reasonably achievable. As a result, SIB-VMAT showed superior dose conformity for the PTV (p<0.001). Although the lung V5Gy was significantly increased (p<0.001), the V20Gy and MLD showed no significant increase. The heart V30-50Gy showed a > 20% reduction in the mean against 3D-CRTs. Our results demonstrate the feasibility of SIB-VMAT for the treatment of middle or lower esophageal cancer with ENI. Although attention should be paid to the low-dose area of the lungs, SIB-VMAT would be a promising treatment option with improved outcomes for esophageal cancer.

    DOI: 10.18926/AMO/56868

    PubMed

    researchmap

  • An Adult Case of Nasal Chondromesenchymal Hamartoma: Imaging Characteristics Including Diffusion-Weighted Images 査読

    Takahiro Kitayama, Shiro Akaki, Kento Hisazumi, Kotaro Yoshio, Daisaku Inoue, Nobuhisa Tajiri, Tsuyoki Shiode, Susumu Kanazawa, Shohei Fujimoto, Kengo Kanai, Yuji Hirata

    Acta Medica Okayama   73 ( 6 )   529 - 532   2019年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nasal chondromesenchymal hamartoma (NCMH), a rare, benign, nasal cavity tumor, typically occurs in children. Differential diagnosis is difficult because NCMH often presents with non-specific findings, including cystic components and invasion of the surrounding area on T2-weighted magnetic resonance images. Here, we present a rare adult case of NCMH, with no clear hyperintensity on diffusion-weighted images (DWI), and bone remodeling on the tumor margins on computed tomography. To the best of our knowledge, this is the first report of DWI on NCMH, and these findings, which suggest benign disease, may be useful in diagnosing NCMH.

    DOI: 10.18926/AMO/57718

    PubMed

    researchmap

  • Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. 査読

    Takeshi Ogata, Kuniaki Katsui, Kotaro Yoshio, Hiroki Ihara, Norihisa Katayama, Junichi Soh, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Acta medica Okayama   72 ( 5 )   507 - 513   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    To clarify the relationship between dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) after surgery in cases of non-small cell lung cancer (NSCLC) treated with induction concurrent chemoradiotherapy (CCRT). Patients with NSCLC treated with induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 2.0 Gy fractions once daily for a total of 46 Gy) before surgery were reviewed. We calculated the percentage of lung volume receiving at least 20 Gy (V20) and the mean lung dose (MLD) for the total lung volume and the lung remaining after resection. Factors affecting the incidence of RP at grade 2 or higher (≥ G2 RP) were analyzed. Eighteen of 49 patients (37%) experienced ≥G2 RP. The V20 and MLD for the lung remaining after resection (V20r and MLDr) were significant predictors according to the multivariate analysis (p=0.007 and 0.041, respectively). The incidence of ≥G2 RP was 8% in patients with V20r<10%, and 13% in patients with MLDr<5.6 Gy, respectively. The optimal approach to reduce the rate of postoperative RP in patients with induction CCRT for NSCLC is to keep the V20r below 10% and/or the MLDr below 5.6 Gy in the radiotherapy planning.

    DOI: 10.18926/AMO/56249

    PubMed

    researchmap

  • Plan quality comparison between 4-arc and 6-arc noncoplanar volumetric modulated arc stereotactic radiotherapy for the treatment of multiple brain metastases 査読

    Kotaro Yoshio, Toshiharu Mitsuhashi, Akihisa Wakita, Takahiro Kitayama, Kento Hisazumi, Daisaku Inoue, Tsuyoki Shiode, Shiro Akaki, Susumu Kanazawa

    Medical Dosimetry   43 ( 4 )   358 - 362   2018年

     詳細を見る

    担当区分:筆頭著者, 責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.meddos.2017.11.007

    researchmap

  • A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer 査読

    Murakami Naoya, Kato Shingo, Nakano Takashi, Uno Takashi, Yamanaka Takeharu, Sakurai Hideyuki, Yoshimura Ryoichi, Hiratsuka Junichi, Kuroda Yuki, Yoshio Kotaro, Itami Jun

    BMC cancer   16 ( 1 )   640 - 640   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BioMed Central  

    BackgroundThis paper describes about a study protocol of phase I/II multicenter prospective clinical trial evaluating the feasibility and efficacy of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced uterine cervical cancer patients.Methods and designPatients with histologically confirmed FIGO stage IB2, IIA2, IIB, and IIIB uterine cervical carcinoma width of which is larger than 5 cm assessed by MRI will be entered to this clinical trial. Protocol therapy is 30-30.6 Gy in 15-17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m2), followed by 24 Gy in 4 fractions of HBT and central shield EBRT up to 50-50.4 Gy in 25-28 fractions. Tumor width is assessed again within one week before the first HBT and if the tumor width is larger than 4 cm, patients proceed to the secondary registration. In phase I section, feasibility of this will be investigated. If less than 10 % out of 20 patients experienced greater than grade 3 acute non-hematologic adverse effects, the study proceeds to phase II part. In phase II part a total of 55 patients will be accrued and the efficacy of the HBT will be investigated comparing with historical control data. If the lower margin of 90 % confidence interval of the 2-year pelvic progression-free survival of the HBT trial is higher than 64 %, the HBT is considered to be more effective than conventional ICBT.DiscussionThe aim of this study is to demonstrate the feasibility and efficacy of the HBT for locally advanced cervical cancer. This trial will clarify the indication, feasibility, and efficacy of this new technique.

    DOI: 10.1186/s12885-016-2543-3

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://link.springer.com/article/10.1186/s12885-016-2543-3/fulltext.html

  • Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab 査読

    Naoya Murakami, Seiichi Yoshimoto, Fumihiko Matsumoto, Takao Ueno, Yoshinori Ito, Satoru Watanabe, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Minako Sumi, Yutaka Saito, Jun Itami

    Journal of Cancer Research and Clinical Oncology   141 ( 1 )   177 - 184   2015年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s00432-014-1801-5

    researchmap

    その他リンク: http://link.springer.com/article/10.1007/s00432-014-1801-5/fulltext.html

  • Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies 査読

    Naoya Murakami, Takahiro Kasamatsu, Minako Sumi, Ryoichi Yoshimura, Ken Harada, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Yoshinori Ito, Jun Itami

    Radiation Oncology   9 ( 1 )   2014年12月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1186/1748-717x-9-31

    researchmap

    その他リンク: http://link.springer.com/article/10.1186/1748-717X-9-31/fulltext.html

  • Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy 査読

    K. Inaba, H. Okamoto, A. Wakita, S. Nakamura, K. Kobayashi, K. Harada, M. Kitaguchi, S. Sekii, K. Takahashi, K. Yoshio, N. Murakami, M. Morota, Y. Ito, M. Sumi, T. Uno, J. Itami

    Journal of Radiation Research   55 ( 6 )   1141 - 1145   2014年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    DOI: 10.1093/jrr/rru052

    researchmap

  • Expression of EpCAM and prognosis in early-stage glottic cancer treated by radiotherapy 査読

    Naoya Murakami, Taisuke Mori, Seiichi Yoshimoto, Yoshinori Ito, Kazuma Kobayashi, Harada Ken, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Minako Sumi, Jun Itami

    The Laryngoscope   124 ( 11 )   E431 - E436   2014年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    DOI: 10.1002/lary.24839

    researchmap

  • Dose error from deviation of dwell time and source position for high dose-rate 192Ir in remote afterloading system 査読

    Hiroyuki Okamoto, Ako Aikawa, Akihisa Wakita, Kotaro Yoshio, Naoya Murakami, Satoshi Nakamura, Minoru Hamada, Yoshihisa Abe, Jun Itami

    Journal of Radiation Research   55 ( 4 )   780 - 787   2014年7月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    DOI: 10.1093/jrr/rru001

    researchmap

  • Localized Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Radiation Therapy: A Long-Term Outcome in 86 Patients With 104 Treated Eyes 査読

    Ken Harada, Naoya Murakami, Mayuka Kitaguchi, Shuhei Sekii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Yoshinori Ito, Minako Sumi, Shigenobu Suzuki, Kensei Tobinai, Takashi Uno, Jun Itami

    International Journal of Radiation Oncology*Biology*Physics   88 ( 3 )   650 - 654   2014年3月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.ijrobp.2013.11.235

    researchmap

  • A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer 査読

    Anticancer Research   34 ( 9 )   5091 - 5098   2014年

     詳細を見る

  • Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma 査読

    Koji Inaba, Ryoji Kushima, Naoya Murakami, Yuuki Kuroda, Ken Harada, Mayuka Kitaguchi, Kotaro Yoshio, Shuhei Sekii, Kana Takahashi, Madoka Morota, Hiroshi Mayahara, Yoshinori Ito, Minako Sumi, Takashi Uno, Jun Itami

    BMC Cancer   13 ( 1 )   2013年12月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1186/1471-2407-13-499

    researchmap

    その他リンク: http://link.springer.com/article/10.1186/1471-2407-13-499/fulltext.html

  • Inverse planning for combination of intracavitary and interstitial brachytherapy for locally advanced cervical cancer 査読

    K. Yoshio, N. Murakami, M. Morota, K. Harada, M. Kitaguchi, K. Yamagishi, S. Sekii, K. Takahashi, K. Inaba, H. Mayahara, Y. Ito, M. Sumi, S. Kanazawa, J. Itami

    Journal of Radiation Research   54 ( 6 )   1146 - 1152   2013年11月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Oxford University Press (OUP)  

    DOI: 10.1093/jrr/rrt072

    researchmap

  • Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma 査読

    SHINYA Takayoshi, FUJII Soichiro, ASAKURA Shoji, TANIGUCHI Toshitaka, YOSHIO Kotaro, ALAFATE Aierken, SATO Shuhei, YOSHINO Tadashi, KANAZAWA Susumu

    Annals of nuclear medicine   26 ( 8 )   616 - 621   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12149-012-0619-y

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://link.springer.com/article/10.1007/s12149-012-0619-y/fulltext.html

  • Two-piece customized mold technique for high-dose-rate brachytherapy on cancers of the buccal mucosa and lip 査読

    Hidenobu Matsuzaki, Mitsuhiro Takemoto, Marina Hara, Teruhisa Unetsubo, Yoshinobu Yanagi, Kuniaki Katsui, Norihisa Katayama, Kotaro Yoshio, Toshihiko Takenobu, Masahiro Kuroda, Susumu Kanazawa, Jun-Ichi Asaumi

    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology   113 ( 1 )   118 - 125   2012年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    Objective. High-dose-rate (HDR) brachytherapy using a customized mold is a minimally invasive treatment for oral cancer; however, it is difficult to use this technique for buccal and lip cancers involving the commissura labiorum, owing to its anatomic form. The purpose of this study was to introduce an improved customized mold consisting of 2 pieces to allow the fixation of molds to these sites. Study design. Five patients with buccal carcinoma and 1 patient with lip carcinoma were treated with this technique after external beam radiotherapy. One patient with neck metastasis underwent both neck dissection and partial tumor esection before HDR brachytherapy. Results. At the end of the follow-up period, 5 patients had no tumor recurrence, and 1 patient had suffered local recurrence. Conclusions. Our technique is a viable therapeutic option for patients with buccal and lip carcinomas for whom the therapeutic modalities are limited by age, performance status, and other factors. © 2012 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.tripleo.2011.06.038

    Scopus

    PubMed

    researchmap

  • The Local Efficacy of I-131 for F-18 FDG PET Positive Lesions in Patients With Recurrent or Metastatic Thyroid Carcinomas 査読

    Kotaro Yoshio, Shuhei Sato, Yoshihiro Okumura, Kuniaki Katsui, Mitsuhiro Takemoto, Etsuji Suzuki, Norihisa Katayama, Mitsumasa Kaji, Susumu Kanazawa

    Clinical Nuclear Medicine   36 ( 2 )   113 - 117   2011年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Ovid Technologies (Wolters Kluwer Health)  

    Purpose: The aim of this study was to evaluate the local efficacy of I-131 for F-18 fluorodeoxyglucose positron emission tomography (FDG PET)-positive lesions.Methods: Whole-body FDG PET/CT was performed on 37 patients (55 cases: 16 men, 21 women; age range: 24-82 years; mean age +/- standard deviation: 60.5 +/- 16.0 years) with differentiated thyroid cancer after total thyroidectomy. The metastatic or recurrent lesions were divided into 5 categories: primary tumor bed, lymph node, lung, bone, and other. The well-defined lesions were measured on CT, and the sizes were compared before and after radioactive iodine therapy.Results: The analysis was performed on 37 patients with 44 lesions (lymph node: 24, lung: 16, bone: 4). Sixteen lesions (70%) were increased and 7 (30%) showed no change or reduction when there was positive accumulation on FDG PET/CT and negative accumulation on I-131 (F(+)I(-)) group. In the positive accumulation for both FDG PET/CT and I-131 (F(+)I(+)) group, 5 lesions (63%) were increased and 3 (37%) showed no change or reduction. There was no significant difference for the tendency to increase in size between the F(+)I(-) and the F(+)I(+) groups.Conclusions: Lesions which show positive accumulations on FDG PET/CT have a greater tendency to increase in size. FDG-avid lesions are resistant to radioactive iodine therapy with or without I-131 uptake.

    DOI: 10.1097/rlu.0b013e318203bb6c

    Web of Science

    researchmap

  • T2^*-weighted Image/T2-weighted Image Fusion in Postimplant Dosimetry of Prostate Brachytherapy 査読

    Katayama Norihisa, Takemoto Mitsuhiro, Yoshio Kotaro, KATSUI Kuniaki, UESUGI Tatsuya, NASU Yasutomo, MATSUSHITA Toshi, KAJI Mitsumasa, KUMON Hiromi, KANAZAWA Susumu

    Journal of radiation research   52 ( 5 )   680 - 684   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Radiation Research Editorial Committee  

    Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.

    DOI: 10.1269/jrr.11011

    CiNii Article

    CiNii Books

    researchmap

  • Oligo-recurrenceの立場からみた単一部位再発が骨転移のみの乳癌に対する放射線治療の意義の検討 査読

    武本 充広, 新部 譲, 兼安 祐子, 吉尾 浩太郎, 片山 敬久, 勝井 邦彰, 黒田 昌宏, 土井原 博義, 松岡 順治, 早川 和重, 永田 靖, 金澤 右

    臨床放射線   54 ( 4 )   516 - 519   2009年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:金原出版(株)  

    Oligo-recurrenceの乳癌骨転移に対する放射線治療の意義を遡及的に検討した。1998年1月〜2003年3月までに乳癌原発巣が制御されており、放射線治療を受けた骨転移が単一部位の再発であった11例について調査した結果、再発時年齢(中央値)は49歳、再発までの期間(中央値)は44ヵ月、再発部位は腰椎4例、骨盤骨3例、その他4例であり、放射線治療における総線量(中央値)は40Gy、全治療期間(中央値)は28日、経過観察期間(中央値)は56ヵ月であった。11例中10例では照射部位の疼痛が制御され、3年生存率77.8%、5年生存率58.4%と長期生存しており、疼痛が再燃した1例は照射線量の最も低い症例であった。長期間の疼痛緩和には高線量の放射線治療に意義があると考えられた。

    researchmap

▼全件表示

MISC

  • III期非小細胞肺癌に対する化学放射線療法後の放射線肺臓炎の検討

    勝井 邦彰, 尾形 毅, 吉尾 浩太郎, 黒田 昌宏, 平木 隆夫, 木浦 勝行, 前田 嘉信, 豊岡 伸一, 金澤 右

    肺癌   60 ( 6 )   577 - 577   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究発表ペーパー・要旨(全国大会,その他学術会議)   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 子宮頸がんに対する密封小線源治療の線量解析に関する検討

    大塚 裕太, 香川 義徳, 青山 英樹, 河合 佑太, 宇野 弘文, 田原 誠司, 片山 敬久, 井原 弘貴, 吉尾 浩太郎

    JART: 日本診療放射線技師会誌   65 ( 9 )   1064 - 1064   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本診療放射線技師会  

    researchmap

  • 同室CTを用いた子宮頸癌に対するIGBTの初期経験

    久住 研人, 片山 敬久, 杉山 聡一, 馬越 紀行, 渡邉 謙太, 井原 弘貴, 勝井 邦彰, 金澤 右, 依田 尚之, 中村 圭一郎, 平松 祐司, 吉尾 浩太郎

    Japanese Journal of Radiology   36 ( Suppl. )   55 - 55   2018年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • SEVERE GASTROINTESTINAL BLEEDING IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA TREATED BY CONCURRENT RADIOTHERAPY AND CETUXIMAB

    Naoya Murakami, Seiichi Yoshimoto, Fumihiko Matsumoto, Takao Ueno, Yoshinori Ito, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekiii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Minako Sumi, Yutaka Saito, Jun Itami

    ANTICANCER RESEARCH   34 ( 10 )   6075 - 6075   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Web of Science

    researchmap

  • Factors Influencing Pain Reduction: Bone Metastases From Renal Cell Carcinoma (RCC) Treated With Radiation Therapy

    K. Harada, K. Kobayashi, M. Kitaguchi, S. Sekii, K. Takahashi, K. Inaba, K. Yoshio, M. Morota, Y. Ito, M. Sumi, J. Itami

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   90   S695 - S695   2014年9月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

  • 【局所進行・再発直腸癌の治療戦略】切除不能な局所進行・再発直腸癌の治療 放射線療法

    伊藤 芳紀, 稲葉 浩二, 村上 直也, 師田 まどか, 角 美奈子, 吉尾 浩太郎, 高橋 加奈, 関井 修平, 北口 真由香, 原田 堅, 小林 和馬, 伊丹 純

    消化器外科   37 ( 2 )   215 - 221   2014年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)へるす出版  

    researchmap

  • 前立腺癌I-125シード治療における術中計画線量と術後線量の比較

    片山 敬久, 山下 真子, 吉尾 浩太郎, 脇 隆博, 尾形 毅, 勝井 邦彰, 金澤 右, 別宮 謙介, 那須 保友, 公文 裕巳, 武本 充広

    Japanese Journal of Radiology   31 ( Suppl.I )   69 - 69   2013年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 前立腺癌中間リスク症例に対する密封小線源永久挿入療法の治療成績

    片山 敬久, 吉尾 浩太郎, 尾形 毅, 脇 隆博, 勝井 邦彰, 金澤 右, 別宮 謙介, 谷本 竜太, 江原 伸, 那須 保友, 武本 充広

    Japanese Journal of Radiology   31 ( Suppl.I )   78 - 78   2013年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 肺癌への定位放射線治療後の18F-FDG-PET検査の有用性の検討

    稲葉 浩二, 原田 堅, 北口 真由香, 山岸 健太郎, 関井 修平, 高橋 加奈, 吉尾 浩太郎, 村上 直也, 馬屋原 博, 伊藤 芳紀, 角 美奈子, 伊丹 純

    日本医学放射線学会秋季臨床大会抄録集   48回   S543 - S543   2012年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 【知っておきたい放射線・粒子線治療】膵癌に対する放射線治療の現況と展望

    伊藤 芳紀, 馬屋原 博, 脇田 明尚, 角 美奈子, 師田 まどか, 村上 直也, 吉尾 浩太郎, 稲葉 浩二, 高橋 加奈, 関井 修平, 原田 堅, 北口 真由香, 山岸 健太郎, 伊丹 純

    臨床外科   67 ( 8 )   1004 - 1010   2012年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医学書院  

    <ポイント>◆局所進行切除不能例に対し,新規抗癌剤併用化学放射線療法により治療成績が向上し,中長期的な生存も図ることができる.◆放射線治療は,腫瘍に対する正確な照射と正常組織への線量低減を図るために,3次元治療計画を行うことが推奨される.◆局所進行切除不能例に対する化学放射線療法前の導入化学療法や,切除例に対する補助化学放射線療法の有用性を検討する臨床試験が施行されている.(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J01539&link_issn=&doc_id=20120725480010&doc_link_id=10.11477%2Fmf.1407104177&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1407104177&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  • 岡山大学病院における前立腺癌密封小線源永久挿入療法の治療成績

    片山 敬久, 武本 充広, 吉尾 浩太郎, 勝井 邦彰, 金澤 右, 能勢 宏幸, 那須 保友, 公文 裕巳

    Japanese Journal of Radiology   30 ( Suppl.I )   71 - 71   2012年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 非小細胞肺がん転移性骨腫瘍に対する放射線治療後の予後/予後因子の検討

    吉尾 浩太郎, 勝井 邦彰, 山下 真子, 多田 明博, 宗田 由子, 武本 充広, 金澤 右, 片山 敬久

    Japanese Journal of Radiology   30 ( Suppl.I )   67 - 67   2012年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 岡山大学病院における前立腺癌密封小線源永久挿入療法の治療成績

    片山 敬久, 武本 充広, 吉尾 浩太郎, 勝井 邦彰, 金澤 右, 能勢 宏幸, 那須 保友, 公文 裕巳

    日本医学放射線学会学術集会抄録集   70回   S130 - S130   2011年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 前立腺に対する精嚢の動きは膀胱・直腸の体積変化と相関するか?

    片山 敬久, 勝井 邦彰, 山下 真子, 吉尾 浩太郎, 武本 充広, 金澤 右, 那須 保友, 公文 裕巳

    日本医学放射線学会学術集会抄録集   69回   S149 - S149   2010年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • 子宮頸癌に対する放射線治療成績の検討

    勝井 邦彰, 吉尾 浩太郎, 片山 敬久, 姫井 健吾, 武本 充広, 中村 圭一郎, 本郷 淳司, 児玉 順一, 平松 祐司, 金澤 右

    日本医学放射線学会学術集会抄録集   69回   S360 - S360   2010年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

▼全件表示

共同研究・競争的資金等の研究

  • 放射線性う蝕から歯を守る~頭頸部がんサバイバーのQOL向上のための基礎研究~

    研究課題/領域番号:23K07156  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松崎 久美子, 吉山 昌宏, 島田 康史, 青山 英樹, 松崎 秀信, 吉尾 浩太郎

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 臓器の呼吸性移動を可視化する複合現実の開発:画像下低侵襲がん治療への実装に向けて

    研究課題/領域番号:23K07083  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松井 裕輔, 諸岡 健一, 平木 隆夫, 櫻井 淳, 吉尾 浩太郎, 冨田 晃司

      詳細を見る

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    researchmap

 

担当授業科目

  • 腫瘍学 (2023年度) 特別  - その他